Avizakimab, formerly known as BOS161721, represents a promising medicinal approach to treating immune-mediated disorders. This antibody substance selectively targets interleukin-18 , a crucial signaling molecule implicated in the pathogenesis of several severe illnesses. Preclinical data have sho… Read More

Rosmantuzumab: A Deep Dive into OMP-131R10 Rosmantuzumab, previously known through OMP-131R10, constitutes a unique monoclonal antibody developed to target granulocyte-macrophage colony-stimulating GM-CSF. Its mode of action requires selectively attaching to GM-CSF, preventing its conne… Read More